NASDAQ:BYSI

BeyondSpring Stock Forecast, Price & News

$9.75
+0.49 (+5.29 %)
(As of 07/28/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.25
$9.87
50-Day Range
$9.26
$12.12
52-Week Range
$8.90
$17.81
Volume130,010 shs
Average Volume230,446 shs
Market Capitalization$381.28 million
P/E RatioN/A
Dividend YieldN/A
Beta0.54
30 days | 90 days | 365 days | Advanced Chart
Receive BYSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BeyondSpring and its competitors with MarketBeat's FREE daily newsletter.


BeyondSpring logo

About BeyondSpring

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

804th out of 2,210 stocks

Pharmaceutical Preparations Industry

396th out of 867 stocks

Analyst Opinion: 3.3Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











BeyondSpring (NASDAQ:BYSI) Frequently Asked Questions

Is BeyondSpring a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BeyondSpring stock.
View analyst ratings for BeyondSpring
or view top-rated stocks.

What stocks does MarketBeat like better than BeyondSpring?

Wall Street analysts have given BeyondSpring a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BeyondSpring wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BeyondSpring's next earnings date?

BeyondSpring is scheduled to release its next quarterly earnings announcement on Thursday, September 2nd 2021.
View our earnings forecast for BeyondSpring
.

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) announced its quarterly earnings results on Tuesday, June, 15th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.10. The firm had revenue of $0.34 million for the quarter.
View BeyondSpring's earnings history
.

How has BeyondSpring's stock been impacted by COVID-19?

BeyondSpring's stock was trading at $11.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BYSI shares have decreased by 14.1% and is now trading at $9.75.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BYSI?

3 equities research analysts have issued 1-year price objectives for BeyondSpring's shares. Their forecasts range from $25.00 to $43.00. On average, they anticipate BeyondSpring's stock price to reach $32.67 in the next year. This suggests a possible upside of 235.0% from the stock's current price.
View analysts' price targets for BeyondSpring
or view top-rated stocks among Wall Street analysts.

Who are BeyondSpring's key executives?

BeyondSpring's management team includes the following people:
  • Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 50)
  • Ms. Elizabeth Adkins Czerepak, Chief Financial Officer (Age 65)
  • Mr. Richard J. Daly M.B.A., Chief Operating Officer (Age 60)
  • Dr. G. Kenneth Lloyd, Chief Scientific Officer (Age 77)
  • Dr. Ramon W. Mohanlal, Exec. VP of R&D, Chief Medical Officer and Director (Age 63)
  • Dr. Gordon L. Schooley, Chief Regulatory Officer (Age 74)
  • Stephen Kilmer, Head of Investor Relations
  • Mr. Gregg Russo, Sr. VP of HR
  • Mr. Paul Friel, Chief Commercial Officer

Who are some of BeyondSpring's key competitors?

What other stocks do shareholders of BeyondSpring own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

When did BeyondSpring IPO?

(BYSI) raised $4 million in an IPO on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

What is BeyondSpring's stock symbol?

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

How do I buy shares of BeyondSpring?

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BeyondSpring's stock price today?

One share of BYSI stock can currently be purchased for approximately $9.75.

How much money does BeyondSpring make?

BeyondSpring has a market capitalization of $381.28 million and generates $180,000.00 in revenue each year. The company earns $-60,970,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does BeyondSpring have?

BeyondSpring employs 91 workers across the globe.

What is BeyondSpring's official website?

The official website for BeyondSpring is www.beyondspringpharma.com.

Where are BeyondSpring's headquarters?

BeyondSpring is headquartered at 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005.

How can I contact BeyondSpring?

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]


This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.